Drug Wars: The Battle to Put a Lid on Rising Prices
In the first of five stories on the battle to address skyrocketing drug prices in the U.S., Institutional Investor looks at how the actions of Turing Pharmaceuticals CEO Martin Shkreli set off a firestorm in Washington.
Khadijah M Silver
November 25, 2015
Martin Shkreli, chief investment officer of MSMB Capital Management, sits in his office in New York, U.S., on Wednesday, Aug. 10, 2011. MSMB made an unsolicited, $378 million takeover bid for Amag Pharmaceuticals Inc. and said it will fire the drugmaker’s top management if successful. Photographer: Paul Taggart/Bloomberg
Paul Taggart/Bloomberg
